



TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

San Diego, CA – December 6, 2007 - TargeGen, Inc. today announced that the Company's recently submitted IND for TG101348 is now active and the Company plans to initiate a multi-center clinical trial of TG101348, an internally discovered, oral, potent, and highly selective JAK2 inhibitor in January, 2008. Additionally, TargeGen announced that a series of presentations related to TG101348 will be made at the 2007 ASH Conference (Atlanta, December 8-11, 2007) by Company scientific staff and outside academic collaborators. Scheduled ASH presentations include:

- Catriona Jamieson – Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera
- Animesh Pardanani & Ayalew Tefferi – Primary Cell Experiments With TG101348, A JAK2 Selective Small Molecule Inhibitor, in The Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12 Mutations
- Gerlinde Wernig & Gary Gilliland – Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera, Session Type
- Betty Tam – TG101348: A Dual Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML
- John Hood – Prospective Identification of Resistance Mutants to the JAK2 Inhibitor TG101348

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoiesis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved specific therapies for PV, ET and PMF. These disorders are estimated to affect approximately 200,000 patients in the United States and more than twice that total worldwide.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH, Innovis Investments, H&Q Capital Management, Pappas Ventures and other investors.

For additional information, contact: TargeGen, Inc.
9380 Judicial Drive
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0160
info@targegen.com
www.targegen.com

--end--